Medicenna Therapeutics (MDNA) Announces the Peer-Reviewed Publication of Clinical Data from Phase 2b Trial Evaluating MDNA55 in Recurrent Glioblastoma

Go back to Medicenna Therapeutics (MDNA) Announces the Peer-Reviewed Publication of Clinical Data from Phase 2b Trial Evaluating MDNA55 in Recurrent Glioblastoma
(NASDAQ: MDNA) Delayed: 2.51 +0.01 (0.40%)
Previous Close $2.50    52 Week High
Open $2.51    52 Week Low
Day High $2.52    P/E N/A 
Day Low $2.48    EPS
Volume 22,317